[1] YUSUF S, JOSEPH P, RANGARAJAN S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study[J]. Lancet, 2020,395(10226): 795-808.
[2] GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018,392(10159): 1736-1788.
[3] TSAO C W, ADAY A W, ALMARZOOQ Z I, et al. Heart disease and stroke statistics-2022 update: A report from the American Heart Association[J]. Circulation, 2022,145(8): e153-e639.
[4] LIBBY P. The changing landscape of atherosclerosis[J]. Nature, 2021,592(7855): 524-533.
[5] WOLF D, LEY K. Immunity and inflammation in atherosclerosis[J]. Circ Res, 2019,124(2): 315-327.
[6] VENKATRAGHAVAN L, TAN T P, MEHTA J, et al. Neutrophil lymphocyte ratio as a predictor of systemic inflammation - A cross-sectional study in a pre-admission setting[J]. F1000Res, 2015,4: 123.
[7] LIBBY P, RIDKER P M, HANSSON G K, et al. Inflammation in atherosclerosis: from pathophysiology to practice[J]. J Am Coll Cardiol, 2009,54(23): 2129-2138.
[8] KAZEM N, HOFER F, KOLLER L, et al. The age-specific prognostic impact of the platelet-to-lymphocyte ratio on long-term outcome after acute coronary syndrome[J]. Eur Heart J Open, 2021,2(1): b31.
[9] OYLUMLU M, OYLUMLU M, ARSLAN B, et al. Platelet-to-lymphocyte ratio is a predictor of long-term mortality in patients with acute coronary syndrome[J]. Postepy Kardiol Interwencyjnej, 2020,16(2): 170-176.
[10] LI W, LIU Q, TANG Y. Platelet to lymphocyte ratio in the prediction of adverse outcomes after acute coronary syndrome: A Meta-analysis[J]. Sci Rep, 2017,7: 40426.
[11] KHATIB-MASSALHA E, MÉNDEZ-FERRER S. Megakaryocyte diversity in ontogeny, functions and cell-cell interactions[J]. Front Oncol, 2022,12: 840044.
[12] LINDEMANN S, KRÄMER B, SEIZER P, et al. Platelets, inflammation and atherosclerosis[J]. J Thromb Haemost, 2007,5(Suppl 1): 203-211.
[13] SHARMA S, TYAGI T, ANTONIAK S. Platelet in thrombo-inflammation: Unraveling new therapeutic targets[J]. Front Immunol, 2022,13: 1039843.
[14] FRANGOGIANNIS N G, SMITH C W, ENTMAN M L. The inflammatory response in myocardial infarction[J]. Cardiovasc Res, 2002,53(1): 31-47.
[15] MEMBERS A T F, MCDONAGH T A, METRA M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail, 2022,24(1): 4-131.
[16] BRIASOULIS A, ANDROULAKIS E, CHRISTOPHIDES T, et al. The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure[J]. Heart Fail Rev, 2016,21(2): 169-176.
[17] ZHANG Y, BAUERSACHS J, LANGER H F. Immune mechanisms in heart failure[J]. Eur J Heart Fail, 2017,19(11): 1379-1389.
[18] DELCEA C, BUZEA C A, VÎJAN A E, et al. The platelet to lymphocyte ratio in heart failure: a comprehensive review[J]. Rom J Intern Med, 2023,61(2): 84-97.
[19] GETAWA S, BAYLEYEGN B. Platelet, neutrophil and lymphocyte quantitative abnormalities in patients with heart failure: a retrospective study[J]. Vasc Health Risk Manag, 2023,19: 69-78.
[20] MURPHY S P, KAKKAR R, MCCARTHY C P, et al. Inflammation in heart failure: JACC State-of-the-Art review[J]. J Am Coll Cardiol, 2020,75(11): 1324-1340.
[21] REICHLIN T, SOCRATES T, EGLI P, et al. Use of myeloperoxidase for risk stratification in acute heart failure[J]. Clin Chem, 2010,56(6): 944-951.
[22] JOURY A, VENTURA H, KRIM S R. Biomarkers in heart failure: relevance in the clinical practice[J]. Int J Cardiol, 2022,363: 196-201.
[23] RUDIGER A, BURCKHARDT O A, HARPES P, et al. The relative lymphocyte count on hospital admission is a risk factor for long-term mortality in patients with acute heart failure[J]. Am J Emerg Med, 2006,24(4): 451-454.
[24] RICHARDS G H C, HONG K L, HENEIN M Y, et al. Coronary artery ectasia: review of the non-atherosclerotic molecular and pathophysiologic concepts[J]. Int J Mol Sci, 2022,23(9): 5195.
[25] KUNDI H, GÖK M, ÇETIN M, et al. Relationship between platelet-to-lymphocyte ratio and the presence and severity of coronary artery ectasia[J]. Anatol J Cardiol, 2016,16(11): 857-862.
[26] ROJAS-MILÁN E, LEÓN C E M, GARCÍA-RINCÓN A, et al. Cardiovascular risk factors associated with coronary ectasia and acute myocardial infarction[J]. Gac Med Mex, 2021,157(6): 604-609.
[27] OZDEMIR E, SAFAK O, ALTIN M P, et al. Correlation between the severity of coronary artery ectasia and monocyte/lymphocyte, platelet/lymphocyte, and HDL/LDL ratios[J]. J Coll Physicians Surg Pak, 2020,30(3): 235-239.
[28] ANTONIADIS A P, CHATZIZISIS Y S, GIANNOGLOU G D. Pathogenetic mechanisms of coronary ectasia[J]. Int J Cardiol, 2008,130(3): 335-343.
[29] BELHARTY N, FERTAT O, GHALI T E, et al. Ectatic coronary arteries: diversity at its finest[J]. Cureus, 2023,15(5): e38381.
[30] TURHAN H, ERBAY A R, YASAR A S, et al. Plasma soluble adhesion molecules; intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin levels in patients with isolated coronary artery ectasia[J]. Coron Artery Dis, 2005,16(1): 45-50.
[31] CHUNG M K, REFAAT M, SHEN W, et al. Atrial fibrillation: JACC Council Perspectives[J]. J Am Coll Cardiol, 2020,75(14): 1689-1713.
[32] WESTERMAN S, WENGER N. Gender differences in atrial fibrillation: a review of epidemiology, management, and outcomes[J]. Curr Cardiol Rev, 2019,15(2): 136-144.
[33] GUNGOR H, BABU A S, ZENCIR C, et al. Association of preoperative platelet-to-lymphocyte ratio with atrial fibrillation after coronary artery bypass graft surgery[J]. Med Princ Pract, 2017,26(2): 164-168.
[34] DERELI S, BAYRAMOGˇLU A, YONTAR O C. Usefulness of platelet to lymphocyte ratio for predicting recurrence of atrial fibrillation after direct current cardioversion[J]. Ann Noninvasive Electrocardiol, 2019,24(2): e12616.
[35] GARY T, PICHLER M, BELAJ K, et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients[J]. PLoS One, 2013,8(7): e67688.
[36] CORRADI D, CALLEGARI S, MANOTTI L, et al. Persistent lone atrial fibrillation: clinicopathologic study of 19 cases[J]. Heart Rhythm, 2014,11(7): 1250-1258.
[37] SUNBUL M, GERIN F, DURMUS E, et al. Neutrophil to lymphocyte and platelet to lymphocyte ratio in patients with dipper versus non-dipper hypertension[J]. Clin Exp Hypertens, 2014,36(4): 217-221.
[38] BAYRAKCI N, OZKAYAR N, AKYEL F, et al. The platelet-to-lymphocyte ratio as an inflammation marker in non-dipper hypertensive patients[J]. Hippokratia, 2015,19(2): 114-118.
[39] SONG Y, KWON J H, KIM J Y, et al. The platelet-to-lymphocyte ratio reflects the severity of obstructive sleep apnea syndrome and concurrent hypertension[J]. Clin Hypertens, 2016,22: 1.
[40] CAO G, LI J, WANG W, et al. The relationship between the neutrophil to lymphocyte ratio, the platelet to lymphocyte ratio, and cardiac syndrome X[J]. Risk Manag Healthc Policy, 2022,15: 427-433. |
